GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis
GLP-1 drugs show no increased psychiatric risk in adolescents and may actually lower suicidal ideation, easing concerns for teens with obesity or diabetes.
This meta-analysis of 11 studies (9 RCTs + 2 observational, n=10,175 adolescents) found that GLP-1 receptor agonists are not associated with higher rates of suicidal behavior or depression in adolescents, and may actually reduce the risk of suicidal ideation. These findings provide important reassurance for clinicians prescribing GLP-1 RAs to adolescents with obesity or type 2 diabetes amid regulatory concerns about psychiatric adverse events.
What the study was
- Study design
- Systematic review and meta-analysis of RCTs and observational cohort studies
- Population
- Adolescents with overweight, obesity, or type 2 diabetes prescribed GLP-1 receptor agonists
- Sample size
- 10175
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Diabetes, Obesity & Metabolism
Why it surfaced
High-quality meta-analysis (9 RCTs + 2 observational, n>10k) directly addressing a major regulatory concern: psychiatric safety of GLP-1 RAs in adolescents. Finding is clinically actionable immediately — provides reassurance to prescribers and regulators. No evidence of increased suicide risk; possible protective effect on suicidal ideation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.